Ajay Gupta is a Cardiology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2 Brighton Rd Ste 400
Clifton, NJ 070121670
Telephone
862-249-4904Provider last certified this registry record 10 Jan 2024.
Clinical trials
- Comparing Accuracy Between Cuffless Wrist Worn and Cuffed Ambulatory BP Monitoring Devices
Sponsor: Queen Mary University of London
- SCRATCH-HTN Study: Evaluating Autonomic Neuromodulation Using Trans-cutaneous Vagal Stimulation in Hypertensive Patients
Sponsor: Queen Mary University of London
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20251 payment
- Amgen Inc.Program year20253 payments
- ABIOMEDProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
72.5%Beta blocker16.5%Metoprolol Succinate50%Metoprolol Tartrate22%Atenolol13%Carvedilol9%Labetalol Hcl7%Part D<11 patientsStatin14.7%Atorvastatin Calcium55%Rosuvastatin Calcium17%Simvastatin16%Pravastatin Sodium12%Part D≥58 patients+ 11 more classes in this area
Blood & clotting
13.5%P2Y12 inhibitor8.2%Clopidogrel100%Part D≥59 patientsFactor Xa inhibitor4.6%Eliquis100%Part D≥22 patients+ 1 more class in this area
Metabolism & gastrointestinal
8.9%Biguanide (metformin)3.6%Metformin Hcl86%Metformin Hcl Er14%Part D<11 patientsProton pump inhibitor3.1%Omeprazole59%Pantoprazole Sodium25%Esomeprazole Magnesium16%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”